Industries: Healthtech, Robotics, Industry 4.0
Funding stage: Series B (5 M EUR - < 20 M EUR) Founded: 2014 Employees: From 1 to 5
Business model: Others Target: Business
Development of first-in-class drugs for precision treatment of MDR gram-negative infections. ABAC shall extensively apply the PasNas Technology Platform to discover novel active compounds against the "big four" gram-negative bacteria.
Minority stake unknown %
Investors: PONTIFAX, GLOBAL HEALTH SCIENCE FUND, CAIXA CAPITAL RISC, DEBIOPHARM INNOVATION FUND Y FERRER
Source: Press releases , newsletters & platforms , company websites , annual reports & accounts , regulatory body sites & stock exchanges
We are continually updating our list of new startups so please let us know if you have recently started one.